<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02396758</url>
  </required_header>
  <id_info>
    <org_study_id>EKOS-12</org_study_id>
    <nct_id>NCT02396758</nct_id>
  </id_info>
  <brief_title>Optimum Duration of Acoustic Pulse Thrombolysis Procedure in Acute Pulmonary Embolism</brief_title>
  <acronym>OPTALYSE PE</acronym>
  <official_title>Study of the Optimum Duration of Acoustic Pulse Thrombolysis Procedure in the Treatment of Acute Submassive Pulmonary Embolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EKOS Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EKOS Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to determine the optimum dose of thrombolytic and duration of
      the ultrasound procedure as a treatment for acute submassive pulmonary embolism.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects with pulmonary embolism with a RV/LV &gt;0.9 and hemodynamically stable who meet all
      eligibility criteria and sign informed consent will be randomized to one of 4 treatment
      groups (see below). 48 hours after the start of treatment, a repeat CTA will be obtained and
      a RV/LV obtained. Thereafter, subjects will be followed for 12 months and an echocardiogram
      obtained at each clinic visit. Subjects will be monitored for occurrence of repeat PE and
      other serious adverse events.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 12, 2015</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Actual">November 30, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>improvement in RV/LV</measure>
    <time_frame>48 hrs</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Pulmonary Embolism and Thrombosis</condition>
  <arm_group>
    <arm_group_label>2 hours APT Procedure and 4/8 mg rtPA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 hr treatment with EkoSonic Endovascular System and either 4 or 8 mg of rtPA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4 hours APT Procedure and 4/8 mg rtPA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4 hr treatment with EkoSonic Endovascular System and either 4 or 8 mg of rtPA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6 hours APT Procedure and 6/12 mg rtPA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>6 hr treatment with EkoSonic Endovascular System and either 6 or 12 mg of rtPA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6 hours APT Procedure and 12/24 mg rtPA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>6 hr treatment with EkoSonic Endovascular System and either 12 or 24 mg of rtPA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tbd</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>x hr treatment with EkoSonic Endovascular System and either x or x mg of rtPA</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EkosSonic Endovascular System plus thrombolytic</intervention_name>
    <arm_group_label>2 hours APT Procedure and 4/8 mg rtPA</arm_group_label>
    <arm_group_label>4 hours APT Procedure and 4/8 mg rtPA</arm_group_label>
    <arm_group_label>6 hours APT Procedure and 6/12 mg rtPA</arm_group_label>
    <arm_group_label>6 hours APT Procedure and 12/24 mg rtPA</arm_group_label>
    <arm_group_label>tbd</arm_group_label>
    <other_name>Acoustic Pulse Thrombolysis Procedure (APT Procedure)</other_name>
    <other_name>EKOS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female ≥ 18 years of age and ≤ 75 years of age

          2. CTA evidence of proximal PE (filling defect in at least one main or lobar pulmonary
             artery)

          3. PE symptom duration ≤14 days

          4. Submassive PE: RV/LV diameter ≥ 0.9 from CTA and hemodynamically stable

          5. Must be treated within 48 hours of diagnosis of PE by CTA

          6. Signed Informed consent obtained from subject or Legally Authorized Representative -

        Exclusion Criteria:

          1. Stroke or transient ischemic attack (TIA), head trauma, or other active intracranial
             or intraspinal disease within one year

          2. Recent (within one month) or active bleeding from a major organ

          3. Major surgery within seven days of screening for study enrollment

          4. Clinician deems the subject high-risk for catastrophic bleeding

          5. History of heparin-induced thrombocytopenia (HIT)

          6. Catheter-based pharmacomechanical treatment for PE within 3 days of study enrollment

          7. Systolic blood pressure (SBP) less than 90 mm Hg and/or use of vasopressors

          8. Cardiac arrest (including pulseless electrical activity and asystole) requiring active
             cardiopulmonary resuscitation (CPR)

          9. Evidence of irreversible neurological compromise

         10. Life expectancy &lt; one year

         11. Use of thrombolytics or glycoprotein IIb/IIIa antagonists within 3 days prior to
             inclusion in the study

         12. Out-of-Range Laboratory Values: Hematocrit &lt; 30%, Platelets &lt; 100 thousand/μL, INR &gt;
             3,

         13. Creatinine outside the normal range for the treating institution

         14. Subject is pregnant (positive pregnancy test; women of childbearing capacity must be
             tested) or breast feeding

         15. Active cancer (metastatic, progressive, or treated within the last 6 months).
             Exception: subjects with non-melanoma primary skin cancers are eligible to participate
             in the study

         16. Known allergy, hypersensitivity, or thrombocytopenia from heparin, r-tPA, or iodinated
             contrast except for mild-moderate contrast allergies for which steroid pre-medication
             can be used -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Victor Tapson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cedar Sinai, Los Angeles</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cedars Sinai</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tallahassee Research Institute</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Hospital Tampa</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Piedmont Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent Medical Group</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jewish Hospital</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Jefferson General Hospital</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Detroit Medical Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spectrum Health</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NY-Presbyterian / Weill Cornell Med Cntr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Carmel health system</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC Hamot</name>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <zip>16507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lankenau Medical Center</name>
      <address>
        <city>Wynnewood</city>
        <state>Pennsylvania</state>
        <zip>19096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Sugarland Hospital</name>
      <address>
        <city>Richmond</city>
        <state>Texas</state>
        <zip>77469</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 10, 2015</study_first_submitted>
  <study_first_submitted_qc>March 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2015</study_first_posted>
  <last_update_submitted>March 17, 2017</last_update_submitted>
  <last_update_submitted_qc>March 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Embolism and Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrinolytic Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

